Stay updated with breaking news from டெக் சோங். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Share this article Share this article NYON, Switzerland, Jan. 28, 2021 /PRNewswire/ 12-month results from the PRESTIGE Below-the-Knee (BTK) study have been presented as a Late Breaking Trial at LINC 2021. The objective of this clinical investigation has been to evaluate safety and performance outcomes of SELUTION SLR™, MedAlliance s novel sirolimus-eluting balloon, for the treatment of long tibial occlusive lesions (TASC C & D) in patients with Critical Limb Ischemia (CLI). 12-Month Below-the-Knee Data with MedAlliance s SELUTION SLR™ Presented as Late Breaking Trial at LINC The Primary Patency Rate was 78% and the rate of wound healing was 81%. Freedom from Target Lesion Revascularization (TLR) was exhibited by 93% of patients and 84% demonstrated Amputation Free Survival (AFS). All these figures have been sustained from the six-month data. ....
12-Month Below-the-Knee Data with MedAlliance s SELUTION SLR Presented as Late Breaking Trial at LINC NYON, Switzerland, Jan. 28, 2021 /PRNewswire/ 12-month results from the PRESTIGE Below-the-Knee (BTK) study have been presented as a Late Breaking Trial at LINC 2021. The objective of this clinical investigation has been to evaluate safety and performance outcomes of SELUTION SLR, MedAlliance s novel sirolimus-eluting balloon, for the treatment of long tibial occlusive lesions (TASC C & D) in patients with Critical Limb Ischemia (CLI). The Primary Patency Rate was 78% and the rate of wound healing was 81%. Freedom from Target Lesion Revascularization (TLR) was exhibited by 93% of patients and 84% demonstrated Amputation Free Survival (AFS). All these figures have been sustained from the six-month data. ....
12-Month Data Presented for MedAllianceâs Selution SLR in BTK Lesions Created with Sketch. January 28, 2021 MedAlliance announced that 12-month results from the PRESTIGE below-the-knee (BTK) study were presented as a late-breaking trial at LINC 2021, the Leipzig Interventional Course held as a virtual event January 25-29. The study sought to evaluate the safety and performance of the Selution SLR, the company’s sirolimus-eluting balloon for the treatment of long tibial occlusive lesions (TASC C & D) in patients with critical limb ischemia. According to the company, PRESTIGE is a prospective, single-center, physician-initiated clinical study conducted by Associate Professor Tze Tec Chong, MD, and Tjun Yip Tang, MD, who are Senior Consultants in the Department of Vascular Surgery at Singapore General Hospital in Singapore. ....
28 gennaio 2021 17:40 Fonte: Adnkronos #salute-e-benessere NYON, Switzerland, Jan. 28, 2021 /PRNewswire/ 12-month results from the PRESTIGE Below-the-Knee (BTK) study have been presented as a Late Breaking Trial at LINC 2021. The objective of this clinical investigation has been to evaluate safety and performance outcomes of SELUTION SLR™, MedAlliance s novel sirolimus-eluting balloon, for the treatment of long tibial occlusive lesions (TASC C & D) in patients with Critical Limb Ischemia (CLI). The Primary Patency Rate was 78% and the rate of wound healing was 81%. Freedom from Target Lesion Revascularization (TLR) was exhibited by 93% of patients and 84% demonstrated Amputation Free Survival (AFS). All these figures have been sustained from the six-month data. ....